ChAdOx1 nCoV-19 vaccine shows lower reactogenicity profile in older adults than in younger adults Jan. 7, 2021
ID-93/GLA-SE tuberculosis vaccine demonstrates safety and immunogenicity in phase IIa trial Jan. 5, 2021
RedHill reports topline phase II data on opaganib in patients hospitalized with COVID-19 pneumonia Jan. 4, 2021
ImmunoPrecise Antibodies joins consortium to develop SARS-CoV-2-specific therapeutic nanomedicine Dec. 31, 2020
RSS